Union City, CA, United States of America

Jennifer R Zhang

USPTO Granted Patents = 48 (Patent Applications = 20)

CIPO Patents = 11 (Patent Applications = 14)

EPO Patents = 22 (Patent Applications = 29)

Average Co-Inventor Count = 10.2

ph-index = 21

Forward Citations = 873(Granted Patents)

Location History:

Foster City, CA (US) (2007 - 2014)
Union City, CA (US) (2014 - 2024)

Company Filing History:

46 out of 924

Gilead Sciences, Inc.

Years Active: 2007-2025

Loading Chart...

Areas of Expertise:

KRAS G12D Modulating Compounds

Bridged Tricyclic Carbamoylpyridone Compounds

Therapeutic Compounds

Capsid Inhibitors

Substituted Pyridotriazine Compounds

Antiviral Phosphonate Analogs

Pyrido(3,2-d)pyrimidines

Protein Kinase Inhibitors

Immuno-Modulatory Activity

Anti-Cancer Phosphonate Analogs

Inhibitors of Flaviviridae Viruses

Modulators of Toll-Like Receptor 7

48 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12448400 - KRAS G12D modulating compounds (2025-10-21),

2. 12421235 - Bridged tricyclic carbamoylpyridone compounds and uses thereof (2025-09-23),

3. 12404262 - Therapeutic compounds for HIV virus infection (2025-09-02),

4. 12227520 - Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use (2025-02-18),

5. 12187734 - Substituted pyridotriazine compounds and uses thereof (2025-01-07),

6. 12084467 - Therapeutic compounds for HIV virus infection (2024-09-10),

7. 12077537 - Capsid inhibitors for the treatment of HIV (2024-09-03),

8. 11993583 - Therapeutic compounds (2024-05-28),

9. 11897892 - Substituted pyridotriazine compounds and uses thereof (2024-02-13),

10. 11753399 - Therapeutic compounds (2023-09-12),

11. 11680064 - Capsid inhibitors for the treatment of HIV (2023-06-20),

12. 11613546 - Substituted pyridotriazine compounds and uses thereof (2023-03-28),

13. 11548902 - Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use (2023-01-10),

14. 11267801 - Therapeutic compounds (2022-03-08),

15. 11117886 - Methods and intermediates for preparing therapeutic compounds (2021-09-14),

Title: **Innovations and Contributions of Jennifer R Zhang**

Introduction

Jennifer R Zhang, based in Union City, CA, is an accomplished inventor with an impressive portfolio of 45 patents. Her work primarily focuses on developing innovative pharmaceutical compounds aimed at treating critical health issues, particularly human immunodeficiency virus (HIV) infection.

Latest Patents

Among her latest patents, Zhang has developed bridged tricyclic carbamoylpyridone compounds, which possess formulas that include stereoisomers and pharmaceutically acceptable salts. These compounds hold promise for treating or preventing HIV infection. Additionally, she has created substituted pyridotriazine compounds, which are involved in similar therapeutic applications. This disclosure includes methods for the preparation and use of such compounds, along with pharmaceutical compositions containing them.

Career Highlights

Throughout her influential career, Jennifer R Zhang has been associated with notable organizations such as Gilead Sciences, Inc. and Pfizer Corporation. Her efforts in these companies have significantly contributed to advancements in pharmaceutical research and development.

Collaborations

In her professional journey, Zhang has collaborated with esteemed colleagues, including Winston C Tse and Scott D Schroeder. These partnerships have fostered innovative approaches to drug development and have furthered the understanding of complex medicinal compounds.

Conclusion

Jennifer R Zhang's contributions to the field of pharmaceutical inventions underscore her role as a pivotal figure in the fight against HIV. Her extensive patent portfolio and collaborations with leading organizations make her a key innovator in the industry, paving the way for future breakthroughs in treatment options.

This text is generated by artificial intelligence and may not be accurate.